Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-10-01 14:19:25 - browse：76

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： DeSantis wants to import drugs. Biden’s FDA blasted his plan

WSS

Cassava reveals details — and problems — with Alzheimer's study

Telehealth options flood the market as retailers push virtual care

Health officials lay out plans to cope with respiratory virus season

Medtronic CEO on promising devices for diabetes, hypertension

Emergency medicine has repudiated 'excited delirium.' Now what?

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

leisure time

Wikipedia

hotspot

At least 13 dead in Texas as scorching temps continue

CDC recommends rationing of RSV shot due to shortages

The cancer drug shortage isn’t new — and neither are the solutions

The pink breast cancer awareness ribbon needs a redesign

BioMarin wins approval for gene therapy to treat hemophilia A

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Cancer drug shortages should be causing more outrage

CDC says it’s too soon to assess risk posed by Covid subvariant

Alkermes shareholders re

Cassava reveals details — and problems — with Alzheimer's study

hotspot

Physician subsidies by hospitals soar in wake of No Surprises Act

WHO may add ‘noma' to its list of neglected tropical diseases

The pink breast cancer awareness ribbon needs a redesign

The pink breast cancer awareness ribbon needs a redesign

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Telehealth options flood the market as retailers push virtual care

Wikipedia

knowledge

explore

explore